PCE Home Study
Influenza Management in the High-Risk Patient
Release Date: October 31, 2020
Expiration Date: October 30, 2021
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
Each year, seasonal influenza is a significant contributor to illness, hospitalization, and mortality worldwide. The burden of seasonal influenza is now complicated by the COVID-19 pandemic, which creates additional challenges in diagnosis and management. Nonetheless, for patients at high risk for influenza complications, antiviral medications offer an opportunity to reduce both the intensity and duration of illness, thus diminishing the risk for life-threatening complications. In this activity, an expert in infectious diseases provides clear guidance on managing influenza—in both children and adults who are at high risk for complications.
Format
Clinical review and case study
Learning Objectives
After completing this activity, participants should be better able to:
- Describe available and emerging options for prevention and treatment of influenza
- Identify patients at high risk for complications of influenza
- Individualize influenza treatment in pediatric patients based on current recommendations
Target Audience
NPs and PAs
Faculty
Paul G. Auwaerter, MD
- Sherrilyn and Ken Fisher Professor of Medicine
- Divisions of Infectious Diseases and General Internal Medicine
- Clinical Director
- Division of Infectious Diseases
- Johns Hopkins School of Medicine
- Baltimore, Maryland
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Susanne J. Phillips, DNP, APRN, FNP-BC, University of California, Irvine, Irvine, California
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until October 30, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Benjamin Taylor, PhD, PA-C, Augusta University, Augusta, Georgia
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; Genentech, a member of the Roche Group; Novo Nordisk Inc.; Sanofi Genzyme; and Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Auwaerter: advisory board: Adaptive Biotechnologies, DiaSorin; stock options: Johnson & Johnson.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: October 31, 2020
Expiration date: October 30, 2021
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97220CPCE-7B